Spyre Therapeutics (SYRE) S-8 Registration of securities for employees

0001636282SPYRE THERAPEUTICS, INC.S-8S-8EX-FILING FEESxbrli:sharesiso4217:USDxbrli:pure000163628212025-02-272025-02-27000163628222025-02-272025-02-2700016362822025-02-272025-02-27

Calculation of Filing Fee Tables

FORM S-8 

(Form Type)

Spyre Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

Security Type	Security Class Title (1)	Fee Calculation Rule	Amount Registered	Proposed Maximum Offering Price Per Unit	Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee
Equity	Common stock, par value $0.0001 per share	Rule 457(a) (2)	3,814,905 (3)	$21.56	$82,249,351.80	0.0001531	$12,592.38
Equity	Common stock, par value $0.0001 per share	Rule 457(a) (4)	602,570 (5)	$18.33	$11,045,108.10	0.0001531	$1,691.01
Total Offering Amounts					$93,294,459.90		$14,283.39
Total Fee Offsets							—
Net Fee Due							$14,283.39

(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s common stock, par value $0.0001 (the “Common Stock”), that may be issued pursuant to the Registrant’s 2016 Equity Incentive Plan (as amended and restated, the “2016 Plan”) and the Registrant's 2016 Employee Stock Purchase Plan (as amended, the “ESPP”), by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the Registrant’s receipt of consideration that increases the number of the outstanding shares of the Registrant’s Common Stock.

(2) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) of the Securities Act, and based on the average of the high and low sale prices of the Common Stock, as quoted on The Nasdaq Global Select Market, on February 21, 2025.

(3) Represents 3,814,905 additional shares of Common Stock to be registered and available for grant under the 2016 Plan resulting from the annual 5% increase in the number of authorized shares available for issuance under the 2016 Plan.

(4) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) of the Securities Act, and based on a 15% discount from the average of the high and low sale prices of the Common Stock, as quoted on The Nasdaq Global Select Market, on February 21, 2025, multiplied by 85%, such discount representing the discount offered pursuant to the ESPP.

  

(5) Represents 602,570 additional shares of Common Stock to be registered and available for grant under the ESPP resulting from the annual 1% increase in the number of authorized shares available for issuance under the ESPP.